World News

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among...

Ogkologos - 25 Αυγούστου, 2025

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

Ogkologos - 22 Αυγούστου, 2025

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib...

Ogkologos - 21 Αυγούστου, 2025

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated...

Ogkologos - 20 Αυγούστου, 2025

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in...

Ogkologos - 19 Αυγούστου, 2025

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

Ogkologos - 18 Αυγούστου, 2025

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to...

Ogkologos - 14 Αυγούστου, 2025

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated...

Ogkologos - 14 Αυγούστου, 2025

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

Ogkologos - 14 Αυγούστου, 2025

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

Ogkologos - 13 Αυγούστου, 2025

1...414243...432 Σελίδα 42 από 432

MOST POPULAR

2022 ASCO Annual Meeting Research Round Up: Advances in Treating Multiple...

28 Ιουλίου, 2022

Opinion: The Government should not be choosing between investing in staff...

27 Ιουλίου, 2022

Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers

7 Ιουλίου, 2026

Talking About Your Sexual Orientation and Gender Identity With Your Cancer...

10 Αυγούστου, 2021

Φόρτωση περισσοτέρων

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among...

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib...

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated...

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in...

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to...

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated...

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

MOST POPULAR

2022 ASCO Annual Meeting Research Round Up: Advances in Treating Multiple...

Opinion: The Government should not be choosing between investing in staff...

Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers

Talking About Your Sexual Orientation and Gender Identity With Your Cancer...

HOT NEWS

Facing Crisis After Crisis During Cancer: How to Cope

Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer

Cancer in My Community: Addressing Regional Cancer Disparities in Peru

Coping With Cancer Recurrence: My Perspective As Both a Patient and...

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ